Chiara Rosso
About
Chiara Rosso is a scholar working on Epidemiology, Hepatology and Endocrinology, Diabetes and Metabolism.
According to data from OpenAlex, Chiara Rosso has authored 140 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 108 papers in Epidemiology, 48 papers in Hepatology and 32 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Chiara Rosso's work include Liver Disease Diagnosis and Treatment (92 papers), Diet, Metabolism, and Disease (29 papers) and Hepatitis C virus research (21 papers). Chiara Rosso is often cited by papers focused on Liver Disease Diagnosis and Treatment (92 papers), Diet, Metabolism, and Disease (29 papers) and Hepatitis C virus research (21 papers). Chiara Rosso collaborates with scholars based in Italy, Germany and Belarus. Chiara Rosso's co-authors include Elisabetta Bugianesi, Andrea Marengo, Gian Paolo Caviglia, Maria Lorena Abate, M. Marietti, Angelo Armandi, Davide Giuseppe Ribaldone, Giorgio Maria Saracco, Rinaldo Pellicano and Amalia Gastaldelli and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Hepatology.
In The Last Decade
Chiara Rosso
123 papers receiving 3.5k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Chiara Rosso Italy | 29 | 2.3k | 946 | 933 | 881 | 577 | 140 | 3.5k | ||
| Narci Teoh Australia | 30 | 2.0k 0.9× | 1.4k 1.5× | 1.1k 1.2× | 592 0.7× | 373 0.6× | 50 | 3.8k | ||
| Karen Louise Thomsen Denmark | 27 | 2.1k 0.9× | 574 0.6× | 1.1k 1.2× | 583 0.7× | 395 0.7× | 104 | 3.0k | ||
| Cláudia P. Oliveira Brazil | 36 | 3.0k 1.3× | 754 0.8× | 1.5k 1.6× | 1.1k 1.3× | 724 1.3× | 145 | 4.3k | ||
| Juan Caballería Spain | 33 | 2.5k 1.1× | 1.2k 1.3× | 1.1k 1.2× | 757 0.9× | 309 0.5× | 67 | 4.1k | ||
| Elmar Aigner Austria | 32 | 1.5k 0.6× | 496 0.5× | 509 0.5× | 602 0.7× | 480 0.8× | 126 | 3.8k | ||
| Masafumi Ono Japan | 34 | 3.8k 1.7× | 723 0.8× | 1.9k 2.0× | 1.7k 1.9× | 440 0.8× | 115 | 4.9k | ||
| James P. Luyendyk United States | 41 | 1.7k 0.7× | 1.2k 1.3× | 1.0k 1.1× | 285 0.3× | 279 0.5× | 115 | 4.9k | ||
| Alexander Wree Germany | 35 | 3.5k 1.5× | 2.6k 2.8× | 1.5k 1.6× | 875 1.0× | 493 0.9× | 90 | 6.0k | ||
| Takaomi Kessoku Japan | 28 | 1.9k 0.8× | 687 0.7× | 935 1.0× | 769 0.9× | 322 0.6× | 126 | 3.1k | ||
| Stefano Ballestri Italy | 32 | 4.5k 1.9× | 734 0.8× | 1.6k 1.7× | 2.3k 2.6× | 614 1.1× | 54 | 5.3k |
Countries citing papers authored by Chiara Rosso
Since
Specialization
Citations
This map shows the geographic impact of Chiara Rosso's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chiara Rosso with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chiara Rosso more than expected).
Fields of papers citing papers by Chiara Rosso
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Chiara Rosso. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chiara Rosso. The network helps show where Chiara Rosso may publish in the future.
Co-authorship network of co-authors of Chiara Rosso
This figure shows the co-authorship network connecting the top 25 collaborators of Chiara Rosso. A scholar is included among the top collaborators of Chiara Rosso based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chiara Rosso. Chiara Rosso is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Saba, Francesca, et al.. (2025). Impact of Sexual Dimorphism on Therapy Response in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: From Conventional and Nutritional Approaches to Emerging Therapies. Nutrients. 17(3). 477–477.
2.
Ferro, Arianna, Gian Paolo Caviglia, Chiara Rosso, et al.. (2025). Impact of Metabolic Dysfunction-Associated Steatotic Liver Disease and Associated Comorbidities on Cognitive and Health-Related Quality-of-Life Outcomes in a Mixed Metabolic Dysfunction-Associated Steatotic Liver Disease-Type 2 Diabetes Mellitus Cohort. The American Journal of Gastroenterology. 120(8). 1779–1790.
3.
Rosso, Chiara, Angelo Gallo, W. Trent Franks, et al.. (2025). Exploring Tyramine's Role in the Formation of Supramolecular Adducts with Nonsteroidal Anti‐Inflammatory Drugs. Chemistry - A European Journal. 31(26). e202500080–e202500080.
4.
Rosso, Chiara, et al.. (2025). Clinical Management of Orthodontic Miniscrew Complications: A Scoping Review. Dentistry Journal. 13(12). 582–582.
5.
Sabatini, Silvia, Partho Sen, Fabrizia Carli, et al.. (2024). Hepatic glucose production rises with the histological severity of metabolic dysfunction-associated steatohepatitis. Cell Reports Medicine. 5(11). 101820–101820.
6.
Rosso, Chiara, Gian Paolo Caviglia, Angelo Armandi, et al.. (2024). Response to a 6-month personalized dietary intervention in patients with metabolic dysfunction-associated steatotic liver disease. Digestive and Liver Disease. 56. S55–S55.
7.
Armandi, Angelo, Chiara Rosso, Gian Paolo Caviglia, & Elisabetta Bugianesi. (2024). An updated overview on hepatocellular carcinoma in patients with Metabolic dysfunction-Associated Steatotic Liver Disease: Trends, pathophysiology and risk-based surveillance. Metabolism. 162. 156080–156080.
8.
Armandi, Angelo, Gian Paolo Caviglia, Amina Abdulle, et al.. (2023). Prognostic Value of Simple Non-Invasive Tests for the Risk Stratification of Incident Hepatocellular Carcinoma in Cirrhotic Individuals with Non-Alcoholic Fatty Liver Disease. Cancers. 15(6). 1659–1659.
9.
Saba, Francesca, et al.. (2023). Molecular Mechanisms of Curcumin in the Pathogenesis of Metabolic Dysfunction Associated Steatotic Liver Disease. Nutrients. 15(24). 5053–5053.
10.
Armandi, Angelo, Chiara Rosso, Ramy Younes, et al.. (2023). Cross-Sectional and Longitudinal Performance of Non-Invasive Tests of Liver Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease. Journal of Clinical Medicine. 12(2). 650–650.
11.
Rosso, Chiara, et al.. (2023). Impact of Health Related QoL and Mediterranean Diet on Liver Fibrosis in Patients with NAFLD. Nutrients. 15(13). 3018–3018.
12.
Armandi, Angelo, Chiara Rosso, Gian Paolo Caviglia, et al.. (2022). Crosstalk between Irisin Levels, Liver Fibrogenesis and Liver Damage in Non-Obese, Non-Diabetic Individuals with Non-Alcoholic Fatty Liver Disease. Journal of Clinical Medicine. 11(3). 635–635.
13.
Saponaro, Chiara, Silvia Sabatini, Melania Gaggini, et al.. (2022). Adipose tissue dysfunction and visceral fat are associated with hepatic insulin resistance and severity of NASH even in lean individuals. Liver International. 42(11). 2418–2427.
14.
Foglia, Beatrice, Salvatore Sutti, Stefania Cannito, et al.. (2021). Hepatocyte-Specific Deletion of HIF2α Prevents NASH-Related Liver Carcinogenesis by Decreasing Cancer Cell Proliferation. Cellular and Molecular Gastroenterology and Hepatology. 13(2). 459–482.
15.
Svegliati‐Baroni, Gianluca, Melania Gaggini, Fabrizia Carli, et al.. (2020). Mechanisms for increased risk of diabetes in chronic liver diseases. Liver International. 40(10). 2489–2499.
16.
Caviglia, Gian Paolo, Chiara Rosso, Angelo Armandi, et al.. (2020). Interplay between Oxidative Stress and Metabolic Derangements in Non-Alcoholic Fatty Liver Disease: The Role of Selenoprotein P. International Journal of Molecular Sciences. 21(22). 8838–8838.
17.
Gaggini, Melania, Fabrizia Carli, Chiara Rosso, et al.. (2019). Altered Metabolic Profile and Adipocyte Insulin Resistance Mark Severe Liver Fibrosis in Patients with Chronic Liver Disease. International Journal of Molecular Sciences. 20(24). 6333–6333.
18.
Morello, Elisabetta, Salvatore Sutti, Beatrice Foglia, et al.. (2017). Hypoxia‐inducible factor 2α drives nonalcoholic fatty liver progression by triggering hepatocyte release of histidine‐rich glycoprotein. Hepatology. 67(6). 2196–2214.
19.
Rosso, Chiara, Salvatore Petta, M. Marietti, et al.. (2016). The combination of Index of NASH score and liver stiffness improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with NonAlcoholic Fatty Liver Disease.. Hepatology. 64. 578–578.
20.
Gastaldelli, Amalia, Melania Gaggini, L. Mezzabotta, et al.. (2013). Alteration in lipid metabolism after an oral fat load in subjects with NAFLD.. Diabetologia. 56.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Narci Teoh Breakdown of academic impact, for papers by Karen Louise Thomsen Breakdown of academic impact, for papers by Cláudia P. Oliveira Breakdown of academic impact, for papers by Juan Caballería Breakdown of academic impact, for papers by Elmar Aigner Breakdown of academic impact, for papers by Masafumi Ono Breakdown of academic impact, for papers by James P. Luyendyk Breakdown of academic impact, for papers by Alexander Wree Breakdown of academic impact, for papers by Takaomi Kessoku Breakdown of academic impact, for papers by Stefano Ballestri